Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
350.00
-21.10 (-5.69%)
Oct 30, 2025, 2:27 PM IDT
-5.69%
Market Cap84.44M
Revenue (ttm)n/a
Net Income (ttm)-44.13M
Shares Outn/a
EPS (ttm)-1.93
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,468
Average Volume35,066
Open371.10
Previous Close371.10
Day's Range347.10 - 371.10
52-Week Range309.30 - 682.90
Beta0.90
RSI54.11
Earnings DateNov 28, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 71
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.